Correspondence 0001193125-22-286747 from Cerevel Therapeutics Holdings, Inc. (CIK 0001805387)
Cerevel Therapeutics Holdings, Inc. (CIK 0001805387)
Date: Nov. 16, 2022 · CIK: 0001805387 · Accession: 0001193125-22-286747
AI Filing Summary & Sentiment
File numbers found in text: 333-268235
Letter
CEREVEL THERAPEUTICS HOLDINGS, INC.
222 Jacobs Street, Suite 200
Cambridge MA 02141
VIA EDGAR
November 16, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Re: Cerevel Therapeutics Holdings, Inc.
Acceleration Request for Registration Statement on Form S-3
Filed November 8, 2022
File No. 333-268235
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 18, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable.
If you have any questions regarding this request, please contact Nicole Daley of Goodwin Procter LLP at (617) 570-1354.
Sincerely,
CEREVEL THERAPEUTICS HOLDINGS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP CEREVEL THERAPEUTICS HOLDINGS, INC. 222 Jacobs Street, Suite 200 Cambridge MA 02141 VIA EDGAR November 16, 2022 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Cerevel Therapeutics Holdings, Inc. Acceleration Request for Registration Statement on Form S-3 Filed November 8, 2022 File No. 333-268235 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cerevel Therapeutics Holdings, Inc. hereby requests that the effective date and time of the above-referenced registration statement be accelerated to November 18, 2022, at 4:01 p.m., Eastern Time, or as soon thereafter as practicable. If you have any questions regarding this request, please contact Nicole Daley of Goodwin Procter LLP at (617) 570-1354. Sincerely, CEREVEL THERAPEUTICS HOLDINGS, INC. /s/ Mark Bodenrader Mark Bodenrader Interim Chief Financial Officer cc: N. Anthony Coles, Cerevel Therapeutics Holdings, Inc. Scott M. Akamine, Cerevel Therapeutics Holdings, Inc. John Mei, Cerevel Therapeutics Holdings, Inc. Stuart M. Cable, Goodwin Procter LLP Nicole Daley, Goodwin Procter LLP